We are live on
!
Find out more
GPP
Great Point Partners Portfolio holdings
AUM
$435M
1-Year Est. Return
318.81%
This Fund
S&P 500
This Quarter
Est. Return
+45.71%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$1.25B
AUM Growth
+$294M
(+31%)
Cap. Flow
+$131M
Cap. Flow
% of AUM
10.43%
Top 10 Holdings %
Top 10 Hldgs %
64.99%
Holding
47
New
11
Increased
13
Reduced
7
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CNST
Constellation Pharmaceuticals, Inc.
CNST
|
+$54.1M |
| 2 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$50.3M |
| 3 |
Iovance Biotherapeutics
IOVA
|
+$44M |
| 4 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$37.2M |
| 5 |
Akebia Therapeutics
AKBA
|
+$36.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PTC Therapeutics
PTCT
|
+$70.4M |
| 2 |
XLRN
Acceleron Pharma
XLRN
|
+$46M |
| 3 |
ABMD
Abiomed Inc
ABMD
|
+$31.4M |
| 4 |
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
|
+$26.6M |
| 5 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$17.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CNST
1
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $105M | 8.36% |
3,480,000
+1,502,498
| +76% | +$54.1M |
|
|
2
Iovance Biotherapeutics
IOVA
$1.82B
| $102M | 8.17% |
3,724,976
+1,337,370
| +56% | +$44M |
|
3
Zymeworks
ZYME
$1.61B
| $92.9M | 7.42% |
2,574,688
+250,000
| +11% | +$9.21M |
|
4
Acadia Pharmaceuticals
ACAD
$4.43B
| $87.5M | 6.99% |
1,804,993
-190,754
| -10% | -$9.16M |
|
|
SAGE
5
DELISTED
Sage Therapeutics
SAGE
| $87.4M | 6.99% |
2,102,368
+277,889
| +15% | +$10.1M |
|
|
ARNA
6
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $82M | 6.55% |
1,302,399
+914,900
| +236% | +$50.3M |
|
7
United Therapeutics
UTHR
$25.8B
| $75M | 6% |
620,000
+63,748
| +11% | +$7.17M |
|
8
TG Therapeutics
TGTX
$7.96B
| $64.7M | 5.17% |
3,320,808
+764,484
| +30% | +$12.3M |
|
|
BHVN
9
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $61.5M | 4.91% |
840,900
+258,995
| +45% | +$13.8M |
|
|
GWPH
10
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $55.2M | 4.41% |
450,000
| – | – |
|
|
11
Akebia Therapeutics
AKBA
$354M
| $47.7M | 3.81% |
+3,510,073
| New | +$36.3M |
|
12
MacroGenics
MGNX
$235M
| $41.9M | 3.35% |
+1,500,000
| New | +$26.1M |
|
13
Cytokinetics
CYTK
$10.5B
| $35.8M | 2.87% |
1,520,635
+856,538
| +129% | +$16.1M |
|
|
GBT
14
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $34.2M | 2.74% |
+542,200
| New | +$37.2M |
|
15
Geron
GERN
$828M
| $33.6M | 2.68% |
+15,398,079
| New | +$23M |
|
16
Vericel Corp
VCEL
$2.35B
| $22.3M | 1.78% |
+1,610,154
| New | +$21.8M |
|
17
Prothena Corp
PRTA
$425M
| $21.8M | 1.74% |
2,082,841
| – | – |
|
18
NextCure
NXTC
$16.8M
| $21.4M | 1.71% |
83,306
-26,107
| -24% | -$9.94M |
|
19
Abeona Therapeutics
ABEO
$366M
| $21M | 1.68% |
288,520
| – | – |
|
20
Glaukos
GKOS
$9.83B
| $19.2M | 1.54% |
+500,000
| New | +$18.6M |
|
|
MTEM
21
DELISTED
Molecular Templates, Inc.
MTEM
| $18.6M | 1.48% |
89,693
+34,693
| +63% | +$8.06M |
|
|
22
PTC Therapeutics
PTCT
$5.64B
| $16.7M | 1.34% |
330,000
-1,433,387
| -81% | -$70.4M |
|
|
AXNX
23
DELISTED
Axonics, Inc. Common Stock
AXNX
| $16.1M | 1.29% |
459,503
-83,426
| -15% | -$2.87M |
|
|
SGMO
24
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $14.2M | 1.13% |
1,579,891
+946,386
| +149% | +$8.78M |
|
25
CytomX Therapeutics
CTMX
$675M
| $12.1M | 0.96% |
1,448,604
+1,308,886
| +937% | +$12.2M |
|
Similar funds
GDS
JWM
SWG
SCP
VIM
VDBMI
ACG
TECP
Great Point Partners's Q2 2020 Portfolio in Review
As of Q2 2020, Great Point Partners held 47 positions worth $1.25B, up 31% from $957M the previous quarter. Its ten largest holdings account for 65% of the portfolio.
Great Point Partners deployed $131M of net new capital in Q2 2020, opening 11 new positions and adding to 13 existing holdings. Its largest new stake was Global Blood Therapeutics, Inc.: 542,200 shares worth $34.2M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 90% a quarter earlier.
On the sell side, the largest reduction was PTC Therapeutics, an estimated $70.4M trimmed.
- Great Point Partners's largest Q2 2020 buy was Global Blood Therapeutics, Inc.: 542,200 shares worth $34.2M.
- Great Point Partners added most to Constellation Pharmaceuticals, Inc. in Q2 2020, an estimated $54.1M increase.
- Great Point Partners's biggest Q2 2020 reduction was PTC Therapeutics, cutting an estimated $70.4M.
- Great Point Partners fully exited Abiomed Inc in Q2 2020, selling an estimated $31.4M.
- Great Point Partners's ten largest holdings make up 65% of its $1.25B portfolio in Q2 2020.
- Great Point Partners opened 11 new positions and closed 11 in Q2 2020.
- Great Point Partners's portfolio value rose 31% quarter-over-quarter to $1.25B.
Based on Great Point Partners's 13F filing for Q2 2020, filed 14 Aug 2020.